Simultaneous Quantitative Assay of Six HIV Protease Inhibitors, One Metabolite, And Two Non-Nucleoside Reverse Transcriptase Inhibitors in Human Plasma by Isocratic Reversed-Phase Liquid Chromatography

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Therapeutic Drug Monitoring

• Publication date

  2002-08-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1097/00007691-200208000-00015PMID 12142642
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Lopinavir

  2020cited by this paper
• Efavirenz

  2012cited by this paper
• Amprenavir

  2012cited by this paper
• Sensitive and Rapid Method for the Simultaneous Quantification of the HIV-Protease Inhibitors Indinavir, Nelfinavir, Ritonavir, and Saquinavir in Human Plasma by Reversed-Phase Liquid Chromatography

  2001cited by this paper
• High-performance liquid chromatography of HIV protease inhibitors in human biological matrices.

  2001cited by this paper
• Simultaneous determination of the HIV protease inhibitors indinavir, amprenavir, saquinavir, ritonavir and nelfinavir in human plasma by high-performance liquid chromatography.

  2001cited by this paper
• Simultaneous determination of the HIV-protease inhibitors indinavir, amprenavir, ritonavir, saquinavir and nelfinavir in human plasma by reversed-phase high-performance liquid chromatography.

  2001cited by this paper
• High-performance liquid chromatographic assay to determine the plasma levels of HIV-protease inhibitors (amprenavir, indinavir, nelfinavir, ritonavir and saquinavir) and the non-nucleoside reverse transcriptase inhibitor (nevirapine) after liquid-liquid extraction.

  2001cited by this paper
• Determination of twelve antiretroviral agents in human plasma sample using reversed-phase high-performance liquid chromatography.

  2000cited by this paper
• Simultaneous determination of the HIV protease inhibitors indinavir, amprenavir, saquinavir, ritonavir, nelfinavir and the non-nucleoside reverse transcriptase inhibitor efavirenz by high-performance liquid chromatography after solid-phase extraction.

  2000cited by this paper
• Simultaneous HPLC assay for quantification of indinavir, nelfinavir, ritonavir, and saquinavir in human plasma.

  2000cited by this paper
• Simultaneous determination of the five HIV-protease inhibitors: amprenavir, indinavir, nelfinavir, ritonavir, and saquinavir in human plasma by solid-phase extraction and column liquid chromatography.

  2000cited by this paper
• Antiretroviral therapy.

  2000cited by this paper
• Simultaneous high-performance liquid chromatographic determination of the antiretroviral agents amprenavir, nelfinavir, ritonavir, saquinavir, delavirdine and efavirenz in human plasma.

  2000cited by this paper
• Prise en charge thérapeutique des personnes infectées par le VIH

  2000cited by this paper
• Delavirdine: a review of its use in HIV infection.

  2000cited by this paper
• Pharmacokinetics and Potential Interactions Amongst Antiretroviral Agents Used To Treat Patients with HIV Infection

  1999cited by this paper
• Determination of indinavir in plasma by solid-phase extraction and column liquid chromatography.

  1999cited by this paper
• Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients.

  1999cited by this paper
• High-performance liquid chromatographic method for the simultaneous determination of HIV-1 protease inhibitors indinavir, saquinavir and ritonavir in plasma of patients during highly active antiretroviral therapy.

  1999cited by this paper
• Simultaneous determination of the HIV-protease inhibitors indinavir, nelfinavir, saquinavir and ritonavir in human plasma by reversed-phase high-performance liquid chromatography.

  1999cited by this paper
• INTERET DU SUIVI THERAPEUTIQUE DES INHIBITEURS DE LA PROTEASE (IP) ET DES INHIBITEURS NON NUCLEOSIDIQUES DE LA TRANSCRIPTASE INVERSE (INNTI) DU VIH PA R LA DETERMINATION DE LEURS CONCENTRATIONS PLASMATIQUES

  1999cited by this paper
• Simultaious determination of the HIV protease inhibitors indinavir, nelfinavir, saquinavir and ritonavir in human plasma by reversed-phase high-performance liquid chromatography.

  1999cited by this paper
• Simultaneous quantitative determination of the HIV protease inhibitors amprenavir, indinavir, nelfinavir, ritonavir and saquinavir in human plasma by ion-pair high-performance liquid chromatography with ultraviolet detection.

  1998cited by this paper
• High-performance liquid chromatographic determination of ritonavir in human plasma, cerebrospinal fluid and saliva.

  1998cited by this paper
• Saquinavir

  1998cited by this paper
• Ritonavir

  1998cited by this paper
• Determination of saquinavir in human plasma by high-performance liquid chromatography.

  1997cited by this paper
• Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease.

  1997cited by this paper
• Protease Inhibitors in Patients with HIV Disease

  1997cited by this paper
• 1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity

  1997cited by this paper
• High-performance liquid chromatographic method for the determination of nelfinavir, a novel HIV-1 protease inhibitor, in human plasma.

  1997cited by this paper
• Determination of ritonavir, a new HIV protease inhibitor, in biological samples using reversed-phase high-performance liquid chromatography.

  1997cited by this paper
• Validation of chromatographic methods in biomedical analysis. Viewpoint and discussion.

  1997cited by this paper
• L-735,524: the design of a potent and orally bioavailable HIV protease inhibitor.

  1994cited by this paper

• Bio-analytical Assay Methods used in Therapeutic Drug Monitoring of Antiretroviral Drugs-A Review

  2019cites this paper
• Silent cardiac dysfunction and exercise intolerance in HIV R men receiving combined antiretroviral therapies

  2018cites this paper
• Bio Analytical Method Development Of an Anti-HIV-1 Drug Efavirenz Using High Performance Liquid Chromatography In Human Plasma

  2017cites this paper
• Simple Reversed-Phase High Performance Liquid Chromatographic Estimation of the Antiretroviral Agent Efavirenz from Human Plasma

  2014cites this paper
• Analysis of some antiretroviral drugs in bulk, pharmaceutical formulations and biological fluid

  2012cites this paper
• Exploring dried blood spot sampling technique for simultaneous quantification of antiretrovirals: lamivudine, stavudine and nevirapine in a rodent pharmacokinetic study.

  2012cites this paper
• Population Pharmacokinetic Modeling of the Association between 63396C→T Pregnane X Receptor Polymorphism and Unboosted Atazanavir Clearance

  2010cites this paper
• Interacciones farmacológicas mediadas por el citocromo P-450 en un grupo de pacientes VIH positivos

  2010cites this paper
• Novel Methodology for Antiretroviral Quantitation in the Female Genital Tract

  2009cites this paper
• High-Performance Liquid Chromatography Methods to Simultaneous Determination of Anti-Retroviral Drugs in Biological Matrices

  2009cites this paper
• Monitorização das concentrações plasmáticas de Efavirenz: critérios de aplicabilidade à prática clínica e efeitos do fármaco a longo termo

  2009cites this paper
• QUANTITATIVE ESTIMATION OF NEVIRAPINE BY HIGH PERFORMANCE THIN LAYER CHROMATOGRAPHY

  2009cites this paper
• A liquid chromatography-tandem mass spectrometry assay for quantification of nevirapine, indinavir, atazanavir, amprenavir, saquinavir, ritonavir, lopinavir, efavirenz, tipranavir, darunavir and maraviroc in the plasma of patients infected with HIV.

  2009cites this paper
• Simultaneous quantification of a non-nucleoside reverse transcriptase inhibitor efavirenz, a nucleoside reverse transcriptase inhibitor emtricitabine and a nucleotide reverse transcriptase inhibitor tenofovir in plasma by liquid chromatography positive ion electrospray tandem mass spectrometry.

  2009cites this paper
• Increase in serum bilirubin in HIV/hepatitis-C virus-coinfected patients on atazanavir therapy following initiation of pegylated-interferon and ribavirin

  2008cites this paper
• Impurity profile study of lopinavir and validation of HPLC method for the determination of related substances in lopinavir drug substance.

  2008cites this paper
• High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients.

  2008cites this paper
• Silent cardiac dysfunction and exercise intolerance in HIV+ men receiving combined antiretroviral therapies

  2008cites this paper
• Impact of baseline health and community support on antiretroviral treatment outcomes in HIV patients in South Africa

  2008cites this paper
• Switch from Ritonavir-Boosted to Unboosted Atazanavir Guided by Therapeutic Drug Monitoring

  2008influential citation
• Longitudinal evaluation of cardiovascular disease-associated biomarkers in relation to abacavir therapy

  2008cites this paper
• Quantitation of five nevirapine oxidative metabolites in human plasma using liquid chromatography-tandem mass spectrometry.

  2007cites this paper
• Electrospray tandem mass spectroscopic characterisation of 18 antiretroviral drugs and simultaneous quantification of 12 antiretrovirals in plasma.

  2007cites this paper
• Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial.

  2007cites this paper
• Efficacy and Safety of a Once Daily Regimen with Efavirenz, Lamivudine, and Didanosine, with and without Food, as Initial Therapy for HIV Infection: The ELADI Study

  2007cites this paper
• Development and Validation of a Liquid Chromatographic Method for Determination of Efavirenz in Human Plasma

  2007cites this paper
• Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia

  2007cites this paper
• Influence of liver fibrosis stage on plasma levels of antiretroviral drugs in HIV-infected patients with chronic hepatitis C.

  2007cites this paper
• Simultaneous determination of 8 HIV protease inhibitors in human plasma by isocratic high-performance liquid chromatography with combined use of UV and fluorescence detection: amprenavir, indinavir, atazanavir, ritonavir, lopinavir, saquinavir, nelfinavir and M8-nelfinavir metabolite.

  2007cites this paper
• The use of drug resistance algorithms and genotypic inhibitory quotient in prediction of lopinavir-ritonavir treatment response in human immunodeficiency virus type 1 protease inhibitor-experienced patients.

  2007cites this paper
• Quantitation of antiretrovirals in alternative matrices

  2007cites this paper
• Determination of Amprenavir Total and Unbound Concentrations in Plasma by High-Performance Liquid Chromatography and Ultrafiltration

  2006cites this paper
• Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C-->T polymorphism at the multidrug resistance gene 1.

  2006cites this paper
• Simple determination of the HIV protease inhibitor atazanavir in human plasma by high-performance liquid chromatography with UV detection.

  2006cites this paper
• Simultaneous determination of six HIV protease inhibitors (amprenavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir), the active metabolite of nelfinavir (M8) and non-nucleoside reverse transcriptase inhibitor (efavirenz) in human plasma by high-performance liquid chromatography.

  2006cites this paper
• Efficacy and Tolerability of a Nucleoside Reverse Transcriptase Inhibitor-Sparing Combination of Lopinavir/Ritonavir and Efavirenz in HIV-1-Infected Patients

  2005cites this paper
• Simple and Simultaneous Determination of the HIV-Protease Inhibitors Amprenavir, Atazanavir, Indinavir, Lopinavir, Nelfinavir, Ritonavir and Saquinavir Plus M8 Nelfinavir Metabolite and the Nonnucleoside Reverse Transcriptase Inhibitors Efavirenz and Nevirapine in Human Plasma by Reversed-Phase Liqu

  2005cites this paper
• Development of an assay method for the detection and quantification of protease and non-nucleoside reverse transcriptase inhibitors in plasma and in peripherical blood mononuclear cells by liquid chromatography coupled with ultraviolet or tandem mass spectrometry detection.

  2005cites this paper
• Conventional HPLC method used for simultaneous determination of the seven HIV protease inhibitors and nonnucleoside reverse transcription inhibitor efavirenz in human plasma.

  2005cites this paper
• Clinical benefit of interventions driven by therapeutic drug monitoring

  2005cites this paper
• Simultaneous Quantitative Assay of Atazanavir and 6 Other HIV Protease Inhibitors by Isocratic Reversed-Phase Liquid Chromatography in Human Plasma

  2005cites this paper
• Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects.

  2005cites this paper
• Influence of 516 G 1 T Polymorphisms at the Gene Encoding the CYP 450-2 B 6 Isoenzyme on Efavirenz Plasma Concentrations in HIV-Infected Subjects

  2005cites this paper
• LC Determination of Ritonavir, a HIV Protease Inhibitor, in Soft Gelatin Capsules

  2005cites this paper
• Effects of concentration and temperature on the stability of nevirapine in whole blood and serum.

  2004cites this paper
• Determination of atazanavir and other antiretroviral drugs (indinavir, amprenavir, nelfinavir and its active metabolite M8, saquinavir, ritonavir, lopinavir, nevirapine and efavirenz) plasma levels by high performance liquid chromatography with UV detection.

  2004cites this paper
• Intérêt et limites du suivi thérapeutique des inhibiteurs de la protéase du VIH

  2004cites this paper
• A Validated HPLC Method for the Determination of the Neuraminidase Inhibitor, Zanamivir (GG167), in Spiked Human Plasma and in Pharmaceutical Formulations

  2004cites this paper
• Automated, Fast, and Sensitive Quantification of Drugs in Human Plasma by LC/LC-MS: Quantification of 6 Protease Inhibitors and 3 Nonnucleoside Transcriptase Inhibitors

  2004cites this paper
• Voltammetric Behavior of Indinavir and Determination in Pharmaceutical Dosage Forms

  2004cites this paper
• Preferential isolation of fragmented DNA enhances the detection of circulating mutated k-ras DNA.

  2004cites this paper
• Le suivi thérapeutique des antirétroviraux : théories et controverses

  2004cites this paper
• Antiretroviral drug content in products from developing countries.

  2004cites this paper
• Subnanogram on-line column-switching liquid chromatographic-tandem mass spectrometric quantification method for nelfinavir and methoxyphenol metabolite M1 in rat plasma.

  2004cites this paper
• Analysis of generic nevirapine products in developing countries.

  2003cites this paper
• Clinical use of a simultaneous HPLC assay for indinavir, saquinavir, ritonavir and nelfinavir in children and adults.

  2003cites this paper
• Analysis of generic nevirapine products in developing countries.

  2003cites this paper
• Change in the quality of care delivered to Medicare beneficiaries, 1998-1999 to 2000-2001.

  2003cites this paper
• Therapeutic Drug Monitoring von HIV Proteinaseinhibitoren/Therapeutic Drug Monitoring of HIV Proteinase Inhibitors

  2003cites this paper
• Determination of Nevirapine in Human Plasma by High Performance Liquid Chromatography with Ultraviolet Detection

  2003cites this paper
• A simple HPLC method for simultaneous determination of lopinavir, ritonavir and efavirenz.

  2003cites this paper
• Therapeutic Drug Monitoring of the HIV/AIDS Drugs Abacavir, Zidovudine, Efavirenz, Nevirapine, Indinavir, Lopinavir, and Nelfinavir

  2003cites this paper
• Clinical Use of a Simultaneous HPLC Assay for Indinavir, Saquinavir, Ritonavir, and Nelfinavir in Children and Adults

  2003cites this paper
• Simple and rapid method for the simultaneous determination of the non-nucleoside reverse transcriptase inhibitors efavirenz and nevirapine in human plasma using liquid chromatography.

  2003cites this paper